SOLO PARA USO EN INVESTIGACIÓN. Datos de referencia para investigación de laboratorio. No es consejo médico; no apto para consumo humano.
Peptijournal

Comparar compuestos

Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.

PopularesRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
ARA-290
Mismo objetivo
Incluir al imprimir

Solo afecta la página impresa o el PDF. El aviso de uso exclusivo en investigación siempre se imprime.

Protocolo01
ARA-290

Reparación tisular

Viales · 10 mg

01Protocol

Viales
10 mg
Datos de dosis
Referencia de laboratorio; no indicado

02Quick calculator

Extraer (100u)

—

Concentración

—

mg/mL

03Mechanism of action

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without stimulating red-blood-cell production. It is studied for small-nerve-fibre damage and neuropathic pain.

04Study endpoints

  • Sarcoidosis small-fibre neuropathy RCT: corneal nerve fibre area rose significantly at day 28 in one arm, skin nerve fibres increased, and pain improved in all groups.
  • Type 2 diabetes neuropathy RCT: neuropathic symptoms (PainDetect) improved and HbA1c and lipid profiles improved over 56 days.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • No potential safety issues were identified in the type 2 diabetes trial; trials were small and short.

06Citations

2 referencias · ver